Product Name:5-bromo-6-chloro-N-[4-[chloro(difluoro)methoxy]phenyl]pyridine-3-carboxamide

IUPAC Name:5-bromo-6-chloro-N-[4-(chlorodifluoromethoxy)phenyl]pyridine-3-carboxamide

CAS:1491150-22-1
Molecular Formula:C13H7BrCl2F2N2O2
Purity:95%+
Catalog Number:CM350855
Molecular Weight:412.01

Packing Unit Available Stock Price($) Quantity

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1491150-22-1
Molecular Formula:C13H7BrCl2F2N2O2
Melting Point:-
Smiles Code:O=C(C1=CC(Br)=C(Cl)N=C1)NC2=CC=C(OC(F)(Cl)F)C=C2
Density:
Catalog Number:CM350855
Molecular Weight:412.01
Boiling Point:
MDL No:
Storage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Asciminib
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.